BRIEF-Verrica Pharmaceuticals Announces First Patient Dosed In Phase 3 Program

Reuters
Jan 07
BRIEF-Verrica Pharmaceuticals Announces First Patient Dosed In Phase 3 Program

Jan 7 (Reuters) - Verrica Pharmaceuticals Inc VRCA.O:

  • VERRICA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 PROGRAM EVALUATING YCANTH® (VP-102) FOR THE TREATMENT OF COMMON WARTS

  • VERRICA PHARMACEUTICALS INC - TORII TO FUND FIRST $40 MILLION OF PHASE 3 TRIAL COSTS

Source text: ID:nGNXbR2ysQ

Further company coverage: VRCA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10